Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis

INTRODUCTION: iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) has demonstrated glycaemic efficacy and safety in adults with inadequately controlled type 2 diabetes mellitus (T2DM). Per the European Medicines Agency’s product label, iGlarLixi should be injected once a day within 1 h prior to...

Descripción completa

Detalles Bibliográficos
Autores principales: Haluzík, Martin, Seufert, Jochen, Guja, Cristian, Bonnemaire, Mireille, Bigot, Gregory, Tournay, Mathilde, Kis, János Tibor, Freemantle, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064361/
https://www.ncbi.nlm.nih.gov/pubmed/36787044
http://dx.doi.org/10.1007/s13300-023-01375-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064361/
https://www.ncbi.nlm.nih.gov/pubmed/36787044
http://dx.doi.org/10.1007/s13300-023-01375-8

Ejemplares similares